Author: Gan&Lee Pharmaceuticals

Posted Date:

April 9, 2026

Gan & Lee Pharmaceuticals Signs Exclusive License Agreement with JW Pharmaceutical, the Leading South Korean Pharma, to Advance the Global Commercialization of the Innovative GLP-1 Receptor Agonist Bofanglutide

Gan&Lee Pharmaceuticals

April 9, 2026
Gan & Lee Pharmaceuticals’ Once-Weekly Basal Insulin GZR4 Injection Meets Primary Endpoints in Two Pivotal Phase 3 Clinical Trials: SUPER-1 and SUPER-2

Gan&Lee Pharmaceuticals

March 31, 2026